Halozyme Therapeutics, Inc. (HALO)

16.17
0.23 1.40
NASDAQ
Prev Close 16.40
Open 16.44
Day Low/High 16.09 / 16.55
52 Wk Low/High 13.24 / 21.48
Volume 444.49K
Exchange NASDAQ
Shares Outstanding 145.30B
Market Cap 2.34B
Div & Yield N.A. (N.A)

Latest News

Halo Launches Gilt™ And Hush™ Brands In Southern California For Sale To Dispensaries Through C4 Distro

Halo Launches Gilt™ And Hush™ Brands In Southern California For Sale To Dispensaries Through C4 Distro

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to provide a progress update on its California business.

Halo Labs Reports Record Monthly Revenue In March 2019 US$2.8 Million (CDN $3.7 Million) Approximately

Halo Labs Reports Record Monthly Revenue In March 2019 US$2.8 Million (CDN $3.7 Million) Approximately

Halo Labs Inc . ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF, Germany:A9KN) is pleased to announce that the Company achieved record revenue in March 2019 of approximately US$2.

Halo Labs Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2018

Halo Labs Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2018

Halo Labs Inc . ("Halo" or the "Company") (NEO:HALO, OTC:AGEEF, Germany:A9KN) today released its financial results for the fourth quarter and year ended December 31, 2018.

Halo Labs Granted DTC Eligibility For The U.S. OTC Market

Halo Labs Granted DTC Eligibility For The U.S. OTC Market

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announced it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC.

Halo Labs Continues To Expand Nevada Business

Halo Labs Continues To Expand Nevada Business

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to provide a progress update on its Nevada business.

Halo Labs Announces Repricing Of Convertible Debenture Units And An Increase In The Expected Size Of The Offering

Halo Labs Announces Repricing Of Convertible Debenture Units And An Increase In The Expected Size Of The Offering

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) announces that it has agreed to amend the terms of its previously announced "best efforts" offering (the "Offering") of convertible debenture units (the "Convertible Debenture...

Halo Labs Recruits Two Proven Executives To Bolster California Leadership Team

Halo Labs Recruits Two Proven Executives To Bolster California Leadership Team

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce two key additions to our leadership team.

2 Stocks You Definitely Should Consider Shorting This Week

2 Stocks You Definitely Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

Halo Labs Announces Hush™ And Gilt™ Product Lines To Be Distributed By C4 Distro In Southern California

Halo Labs Announces Hush™ And Gilt™ Product Lines To Be Distributed By C4 Distro In Southern California

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce its partnership to distribute the award-winning Hush™ and Gilt™ product lines through one of Southern California's leading cannabis distributors, C4...

A Biotech Concern, a Silica Producer and Other Stocks That Look Good Short

AYX, HALO, SLCA, HCI and IDCC all recently were downgraded by TheStreet's Quant Ratings.

Halo Labs Announces Short Form Prospectus Offering Of Convertible Debenture Units

Halo Labs Announces Short Form Prospectus Offering Of Convertible Debenture Units

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce that it has filed a preliminary short form prospectus (the "Prospectus") in connection with a "best efforts" offering (the "Offering") of convertible...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMBA, BPY, GRBK, JD, TWI Downgrades: HALO, SFM, XPO Initiations: ILPT Read on to get TheStreet Quant Ratings' detailed report:

Halo Labs Awarded Annual Cannabis Manufacturing License By California, Among The First To Implement Track And Trace (METRC)

Halo Labs Awarded Annual Cannabis Manufacturing License By California, Among The First To Implement Track And Trace (METRC)

Halo Labs Inc . ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce that the Company has 1 of only 52 annual state licenses issued to date and is one of the first operators in California to fully implement California's...

Halozyme To Participate In Upcoming Investor Conferences

Halozyme To Participate In Upcoming Investor Conferences

SAN DIEGO, March 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in two upcoming investor conferences.

Halo Labs Reports Record Monthly Revenue Of Approximately US$2.6 Million (CDN $3.4 Million) In The Shortened Month Of February

Halo Labs Reports Record Monthly Revenue Of Approximately US$2.6 Million (CDN $3.4 Million) In The Shortened Month Of February

Halo Labs Inc.  ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) is pleased to announce that the Company achieved another record setting revenue month in February 2019 of approximately US$2.

Halozyme Announces FDA Approval Of Herceptin Hylecta™

Halozyme Announces FDA Approval Of Herceptin Hylecta™

SAN DIEGO, Feb. 28, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halo Labs Successfully Launches DabTabs™ In Oregon And Nevada

Halo Labs Successfully Launches DabTabs™ In Oregon And Nevada

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, GERMANY: A9KN) is pleased to provide a progress update on the launch of the revolutionary DabTabs™.

Halo Labs Signs Bulk Biomass Procurement And Bulk Extract Supply Agreement With Cannus Partners In California

Halo Labs Signs Bulk Biomass Procurement And Bulk Extract Supply Agreement With Cannus Partners In California

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF) is pleased to announce it has entered into a two-part agreement with Cannus Partners Inc.

Halo Labs To Present At The Gravitas Growth Conference In Vancouver

Halo Labs To Present At The Gravitas Growth Conference In Vancouver

Halo Labs Inc. (NEO: HALO, OTC: AGEEF, GERMANY: A9KN) ("Halo" or the "Company"), a cannabis extraction company that develops and manufactures quality cannabis oils and concentrates, which are the fastest growing segment in the cannabis industry, today...

REPEAT/Halo Labs Commences Trading On The OTCQB Venture Market In The United States Under The Symbol AGEEF

REPEAT/Halo Labs Commences Trading On The OTCQB Venture Market In The United States Under The Symbol AGEEF

Halo Labs Inc . ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, GERMANY: A9KN) is pleased to announce that OTC Markets Group Inc.

Halozyme Reports Fourth Quarter And Full-Year 2018 Results

Halozyme Reports Fourth Quarter And Full-Year 2018 Results

- ENHANZE® Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million -

Halo Labs Reports Record Monthly Revenue Of Approximately US$2.4 Million (CDN $3.1 Million) In January 2019

Halo Labs Reports Record Monthly Revenue Of Approximately US$2.4 Million (CDN $3.1 Million) In January 2019

Halo Labs Inc . ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF) is pleased to announce that the Company achieved record revenue in January 2019 of approximately US$2.

Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call

Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call

SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Argenx And Halozyme Enter Global Collaboration And License Agreement For ENHANZE® Technology

Argenx And Halozyme Enter Global Collaboration And License Agreement For ENHANZE® Technology

--- argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn ---

Halo Labs Provides Operational Update & Announces Closing Of Promissory Note

Halo Labs Provides Operational Update & Announces Closing Of Promissory Note

Halo Labs Inc. (" Halo" or the " Company") (NEO:HALO, OTC:AGEEF) is pleased to provide an operational update given the recent developments at the Company in the past few months and announces the closing of a promissory note financing.

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

- Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation

First Week Of HALO February 15th Options Trading

First Week Of HALO February 15th Options Trading

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

TheStreet Quant Rating: D (Sell)